Today, Teva ... LAI, duvakitug, DARI, and emrusolmin. AUSTEDO: Expected to exceed $2.5 billion in sales by 2027 and exceed $3 billion by 2030. AJOVY: A globally established brand with presence ...

I have the great pleasure of having Teva here with us ... our olanzapine LAI program for schizophrenia, our duvakitug program that's partnered with Sanofi, a first-class biologic that has shown ...

TEL AVIV, Israel and PARSIPPANY, N.J., May 29, 2025 (GLOBE NEWSWIRE) -- Teva ... LAI, duvakitug, DARI, and emrusolmin. AUSTEDO: Expected to exceed $2.5 billion in sales by 2027 and exceed $3 billion ...

Teva outlines acceleration ... assets including olanzapine LAI, duvakitug, DARI, and emrusolmin. AUSTEDO: Expected to exceed $2.5 billion in sales by 2027 and exceed $3 billion by 2030. AJOVY: A ...

Teva's late-stage pipeline includes duvakitug and DARI ... OTC business with a global portfolio of strong local and global brands, outperforming the market with double-digit growth.

Phase 2 topline results for Duvakitug are anticipated in Q4 2024, with potential initiation of Phase 3 studies in the second half of 2025. Additionally, Teva has recently launched Selarsdi and is ...

Phase 2 topline results for Duvakitug are anticipated in Q4 2024, with potential initiation of Phase 3 studies in the second half of 2025. Additionally, Teva has recently launched Selarsdi and is ...

Health Canada has issued a recall for a brand of birth control pills after some packages were packed with extra placebo tablets. The agency says the recall covers Seasonale Tablets made by Teva ...